Gallasus

Gallasus is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for inflammatory and autoimmune diseases. The company's lead research centers on G protein-coupled receptor 35 (GPR35) agonists, which aim to restore intestinal barrier function and reduce inflammation in patients with inflammatory bowel disease (IBD). By targeting mucosal healing rather than just systemic immunosuppression, Gallasus seeks to provide more durable and safer treatment options for ulcerative colitis and Crohn's disease. The company is currently advancing its lead candidates through late-stage pre-clinical development toward IND-enabling studies.